Dosage of Clarithromycin 500 mg for Lower Respiratory Tract Infection
For adults with lower respiratory tract infections (LRTI), clarithromycin 500 mg should be administered twice daily (every 12 hours) for at least 5-7 days, depending on the specific type of LRTI. 1
Specific Dosing by LRTI Type
Community-Acquired Pneumonia (Hospitalized)
- Dose: 250-500 mg orally every 12 hours
- Duration: At least 5 days 1
- Assess clinical response at day 2-3 (fever resolution, lack of radiographic progression)
Acute Bacterial Exacerbation of Chronic Bronchitis
- Dose: 500 mg every 12 hours
- Duration: At least 7 days 1
- Assess response at day 5-7 for symptom improvement
Extended-Release Formulation Alternative
If using the extended-release formulation 2:
- Dose: 1000 mg (two 500 mg tablets) once daily with food
- Duration: 7 days for acute exacerbation of chronic bronchitis or community-acquired pneumonia
- Must be swallowed whole; cannot be crushed, chewed, or broken
Critical Dosing Considerations
Renal Impairment: 2
- Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50%
- No adjustment needed for hepatic impairment alone
Drug Interactions: 2
- When co-administered with atazanavir or ritonavir: Reduce clarithromycin dose by 50%
- Avoid with cisapride, pimozide, lomitapide, lovastatin, or simvastatin (contraindicated)
Duration Nuances
The European Respiratory Society guidelines 1 specify that treatment should continue for at least 7 days for most LRTIs, with the notable exception that clarithromycin (and azithromycin) may be given for shorter courses as specified. The minimum effective duration is at least 5 days for clarithromycin specifically 1.
For Legionella pneumophila infections: Extend treatment to 21 days 1
Common Pitfalls to Avoid
Food requirement for extended-release: The extended-release formulation has approximately 30% lower bioavailability when taken without food 2. Always administer with meals.
Resistance considerations: Clarithromycin should only be used in areas with low rates of resistant Streptococcus pneumoniae 1. Local resistance patterns matter significantly.
Not for viral infections: Do not prescribe for acute bronchitis without suspected pneumonia, common cold, or viral pharyngitis 3
Dose confusion: The 500 mg twice-daily dose is standard for immediate-release tablets. Do not confuse this with the 1000 mg once-daily extended-release dose.
Monitoring Requirements
- Assess clinical response at day 5-7 for non-pneumonia LRTI 1
- For pneumonia, reassess at day 2-3 for fever and radiographic progression 1
- No routine drug level monitoring required 4
The evidence strongly supports 500 mg twice daily as the standard dose for immediate-release clarithromycin in adult LRTIs, with duration tailored to the specific infection type and clinical response.